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Introduction
Crohn’s disease (CD) and ulcerative colitis are 2 main classical types of  inflammatory bowel disease (IBD) 
(1, 2). The etiology of  IBD involves genetic susceptibility and environmental triggers. Over 200 single 
nucleotide polymorphisms (SNPs) have been associated with susceptibility to IBD (3–7). This complex 
genetic network indicates that IBD likely encompasses more than the 2 classical subtypes. Therefore, 
novel, rationally designed biomarkers that can lead to disease stratification and personalized treatments 
are needed (8). One candidate method to subtype CD is to define the morphological patterns of  small 
intestinal Paneth cells based on the intracellular distribution of  granules containing antimicrobial pro-
teins (Paneth cell phenotypes) (7). Paneth cells are specialized secretory cells located at the bases of  the 
crypts of  Lieberkühn in the small intestine (9–11). These cells produce a wide repertoire of  antimicrobial 
BACKGROUND. Morphological patterns of Paneth cells are a prognostic biomarker in Western 
Crohn’s disease (CD) patients, and are associated with autophagy-associated ATG16L1 and NOD2 
variants. We hypothesized that genetic determinants of Paneth cell phenotype in other ethnic CD 
cohorts are distinct but also involved in autophagy.
METHODS. We performed a hypothesis-driven analysis of 56 single nucleotide polymorphisms 
(SNPs) associated with CD susceptibility or known to affect Paneth cell function in 110 Japanese CD 
patients who underwent ileal resection. We subsequently performed a genome-wide association 
analysis. Paneth cell phenotype was determined by defensin-5 immunofluorescence. Selected 
genotype–Paneth cell defect correlations were compared to a Western CD cohort (n = 164).
RESULTS. The average percentage of abnormal Paneth cells in Japanese CD was similar to Western 
CD (P = 0.87), and abnormal Paneth cell phenotype was also associated with early recurrence (P 
= 0.013). In contrast to Western CD, ATG16L1 T300A was not associated with Paneth cell defect 
in Japanese CD (P = 0.20). Among the 56 selected SNPs, only LRRK2 M2397T showed significant 
association with Paneth cell defect (P = 3.62 × 10–4), whereas in the Western CD cohort it was not 
(P = 0.76). Pathway analysis of LRRK2 and other candidate genes with P less than 5 × 10–4 showed 
connections with known CD susceptibility genes and links to autophagy and TNF-α networks.
CONCLUSIONS. We found dichotomous effects of ATG16L1 and LRRK2 on Paneth cell defect 
between Japanese and Western CD. Genes affecting Paneth cell phenotype in Japanese CD were also 
associated with autophagy. Paneth cell phenotype also predicted prognosis in Japanese CD.
FUNDING. Helmsley Charitable Trust, Doris Duke Foundation (grant 2014103), Japan Society for 
the Promotion of Science (KAKENHI grants JP15H04805 and JP15K15284), Crohn’s and Colitis 
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peptides, such as lysozyme and α-defensins, to modulate 
the intestinal microbiome (12–15) and thus are important 
mediators of  the host innate immune response (16, 17).
We have previously shown that in European ancestry 
CD patients from North America, abnormal Paneth cell 
phenotype is associated with variants in ATG16L1 and 
NOD2 genes, both of  which are CD susceptibility genes 
involved in autophagy (18, 19). Furthermore, we have 
also demonstrated that abnormal Paneth cell phenotype 
is associated with mucosal dysbiosis and aggressive dis-
ease course (19, 20). Thus, Paneth cell phenotype is a 
biologically and clinically relevant biomarker that can 
stratify CD patients.
To broaden the applications of  Paneth cell pheno-
type in CD, a more detailed understanding of  the genet-
ic determinants of  Paneth cell phenotype and further 
clinical validation are critical. However, as over 90% of  
Western CD cases are composed of  patients of  Europe-
an ancestry who harbor ATG16L1 T300A and/or NOD2 
CD-risk variants (3, 4), identification of  novel genetic 
determinants in this population is challenging. Thus, 
studying CD patients from other ethnicities, especially 
those who possess a spectrum of  susceptibility genes dis-
tinct from those found in European ancestry CD, would 
be helpful in identifying novel genetic determinants of  
Paneth cell phenotype. The genetic landscape of  CD 
patients from Korea and Japan is partially overlapping 
but largely different than that of  European ancestry CD 
(5, 21–23). In particular, the NOD2 variants associated 
with European ancestry CD are not polymorphic in 
Japanese populations (24). In addition, while ATG16L1 
T300A is polymorphic in Japanese cohorts, it has not 
been associated with CD susceptibility (25). In contrast, SNPs that are more frequently associated with 
CD in Asian populations include those that tag TNFSF15, IL23R, ATG16L2, STAT3, GPR35, MHC Class 
II, and ZNF365, among others (5, 21–23, 25). Therefore, a Japanese CD patient cohort represents a 
unique cohort to identify novel genetic determinants of  Paneth cell phenotypes.
In this study, we hypothesized that novel genetic determinants of Paneth cell defect exist in Japanese CD, 
and that abnormal Paneth cell phenotype would be associated with poor outcome in Japanese CD patients. We 
further hypothesized that these novel genetic determinants of Paneth cell defect in Japanese CD would also be 
associated with autophagy as in North American CD. We found that the prevalence of abnormal Paneth cell 
phenotype in Japanese CD was similar to North American CD. Abnormal Paneth cell phenotype also corre-
lated with more aggressive outcome in Japanese CD. Our hypothesis-driven analysis identified that autophagy-
associated LRRK2, but not ATG16L1, was associated with Paneth cell defect in Japanese CD. In contrast, in 
North American CD, ATG16L1 but not LRRK2 was associated with Paneth cell defect. In addition, unbiased 
genome-wide analysis for Paneth cell phenotype genetic associations identified additional candidate SNPs pre-
dicted to interact with known CD susceptibility genes and jointly affect autophagy or TNF-α signaling.
Results
Paneth cell defects were prevalent in Japanese CD patients. The overall work flow for the determination of  genetic 
associations of  Paneth cell defect in Japanese CD patients is outlined in Figure 1. We first determined the 
percentage of  normal Paneth cells in resection specimens of  adult Japanese CD subjects using a previously 
reported method of  immunofluorescence localization for defensin-5 (20). The staining for defensin-5 was 
specific for Paneth cells and the results were highly correlative to that obtained by lysozyme immunofluo-
rescence (R2 = 0.6451; P < 0.0001) (Supplemental Figure 1; supplemental material available online with this 
Figure 1. Diagram of the genetic–
Paneth cell analysis in Japanese 
Crohn’s disease patients. CD, Crohn’s 
disease; MAF, minor allele frequency.
3insight.jci.org   https://doi.org/10.1172/jci.insight.91917
C L I N I C A L  M E D I C I N E
article; https://doi.org/10.1172/jci.insight.91917DS1). There was a similar range of  intracellular staining 
patterns to those previously observed in multiple North American CD cohorts (19, 20) (Figure 2A). The 
average percentage of  normal Paneth cells was similar between Japanese and North American CD subjects 
(82.13 ± 1.06 vs. 81.9 ± 0.55; P = 0.87) (Figure 2B). As in previous studies, we utilized a cutoff  of  greater 
than or equal to 20% (high abundance) abnormal Paneth cells to define a type I Paneth cell phenotype 
(type II is < 20% abnormal Paneth cells). We found that the prevalence of  type I Paneth cell phenotype in 
Japanese CD subjects was similar to a North American cohort (33% vs. 26%; P = 0.26) (Figure 2B). We 
also examined potential correlations between the clinical data obtained for the Japanese CD subjects and 
Paneth cell phenotypes (Table 1). Of  note, there was no significant difference in the demographics and 
clinical phenotype (Montreal classification) between patients with type I and type II Paneth cell phenotypes 
at time of  resection. In addition, we also examined whether Paneth cell phenotype and/or individual mor-
phology category correlated with the presence or absence of  granuloma. We found that while there was a 
trend in that the percentage of  diminished Paneth cell morphology inversely correlated with the presence of  
granuloma as we have shown previously (19), overall there was no significant correlation between Paneth 
cell phenotype or each Paneth cell morphology category and granuloma (Supplemental Figure 2).
Type I Paneth cell phenotype was associated with poor clinical outcome in Japanese CD. To determine whether 
Paneth cell phenotype also correlated with clinical outcome in patients undergoing resections in Japanese 
CD, we analyzed the clinical outcome only for those patients who had received postoperative prophylactic 
therapy, as postoperative prophylaxis has been shown to be associated with outcome (26). We listed the 
characteristics of  the patients that were included for outcome analysis in Supplemental Table 1. We found 
that in Japanese CD patients, type I Paneth cell phenotype was also associated with shorter time to disease 
recurrence after resection (P = 0.013; hazard ratio = 2.10, 95% CI = 1.04–4.24) (Figure 3). This association 
remained significant in multivariate analysis (Supplemental Table 2), thus replicating the finding that we 
have previously shown in North American CD patients (19).
ATG16L1 T300A was not associated with Paneth cell defect in Japanese CD. We next examined the potential 
associations of  type I Paneth cell phenotype with 56 SNPs, selected based on known CD susceptibility associ-
ations (3, 5, 21–23, 27–29) or known association with Paneth cell function (17) (Supplemental Table 3). These 
SNPs include coding variants for ATG16L1 (T300A) associated with Paneth cell defects in North American 
CD cohorts and in genetic mouse models (18, 19, 30). Among the Japanese CD patients with available geno-
type data (n = 98), we found no significant difference between the numbers of  the ATG16L1 T300A risk allele 
and the percentage of  normal Paneth cells (R2 = 0.01717; P = 0.20) (Figure 4A). In contrast, in North Ameri-
can CD with wild-type NOD2 (to eliminate potential confounding factors from NOD2; n = 97), the numbers 
of  ATG16L1 T300A risk allele correlated with the percentage of  normal Paneth cells (R2 = 0.04387; P = 
0.0395; Figure 4B), a finding that we have shown previously with a smaller CD cohort (18). Of note, the allele 
frequency of  ATG16L1 T300A in our Japanese CD cohort was 40%, a level comparable to what has been 
published (27). Therefore, in contrast to the North American CD, ATG16L1 T300A was not associated with 
the percentage of  normal Paneth cells or type I Paneth cell phenotype in Japanese CD. NOD2, another CD 
susceptibility gene previously shown to be associated with Paneth cell defect in North American CD patients, 
is nonpolymorphic in Japanese patients (31, 32), and thus was not included on the Japonica SNP array.
Figure 2. Type I Paneth cell phenotype was 
prevalent in Japanese Crohn’s disease (CD). (A) 
Representative images of defensin-5 immuno-
fluorescence on Japanese CD resection specimens. 
Scale bar: 10 μm. (B) The distribution of percent-
age of normal Paneth cells in North American 
(n = 164) and Japanese CD (n = 110). P = 0.87 by 
unpaired t test. Error bars represent ± SEM.
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Western CD susceptibility allele LRRK2 M2397T was associated with Paneth cell defect in Japanese CD. Inter-
estingly, the only SNP within the pool of  56 selected alleles for hypothesis-driven correlation analysis that 
showed significant association with Paneth cell defects in Japanese CD was LRRK2 M2397T (Figure 4C). 
The LRRK2 M2397T SNP (rs3761863) is a missense susceptibility allele for European ancestry CD (3, 33), 
and Lrrk2 knockout mice have defective Paneth cells (34). In the Japanese CD cohort, we found that the 
numbers of  the T (risk) allele LRRK2 M2397T correlated with the percentage of  normal Paneth cells (R2 = 
0.247; P = 3.62 × 10–4; Figure 4C). The results suggest that 2 defective copies of  the LRRK2 gene product 
may be required to illicit Paneth cell defects in Japanese CD patients.
Table 1. Characteristics of all Japanese Crohn’s disease patients included in this study
Type I Paneth cell phenotype Type II Paneth cell phenotype P value
n 31 79
Sex (male) 22 (71.0%) 60 (76.0%) 0.630
Mean disease duration in years (range) 17.5 (14.8–20.3) 18.0 (16.2–19.7) 0.786
Mean age at onset (range) 23.8 (21.5–26.2) 23.1 (21.7–24.6) 0.612
Disease OnsetA
A1 4 (12.9%) 11 (13.9%) 1.000
A2 26 (83.9%) 67 (84.8%) 1.000
A3 1 (3.2%) 1 (1.3%) 0.486
Disease Location
L1 3 (9.7%) 12 (15.2%) 0.550
L2 0 0 NA
L3 28 (90.3%) 67 (84.8%) 0.550
Disease Behavior
B1 0 1 (1.3%) 1.000
B2 25 (80.7%) 74 (93.6%) 0.071
B3 20 (64.5%) 36 (45.6%) 0.090
Perianal disease 24 (80%) 59 (75.6%) 0.800
Current smoking 9 (36%) 16 (32%) 0.798
Treatment received prior to surgery
Biologics (Bio) 12 (38.7%) 22 (27.9%) 0.359
Immunomodulator (IM) 5 (16.1%) 7 (8.9%) 0.313
Elemental diet (ED) 12 (38.7%) 18 (22.8%) 0.102
Treatment combination prior to surgery
Only Bio 5 (16.1%) 13 (16.5%) 1.000
Only IM 0 2 (2.5%) 1.000
Only ED 6 (19.4%) 13 (16.5%) 0.781
Bio+IM 1 (3.2%) 4 (5.1%) 1.000
Bio+ED 2 (6.5%) 4 (5.2%) 1.000
ED+IM 0 0 NA
Bio+IM+ED 4 (12.9%) 1 (1.3%) 0.022
Postoperative therapy
None 7 (22.6%) 27 (34.2%) 0.262
Bio 16 (51.6%) 35 (44.3%) 0.529
First use of Bio 10 (32.3%) 20 (25.3%) 0.482
IM 6 (19.4%) 12 (15.2%) 0.579
ED 13 (41.9%) 26 (32.9%) 0.385
Treatment combination
Only Bio 9 (29.0%) 17 (21.5%) 0.457
Only IM 1 (3.2%) 2 (1.8%) 1.000
Only ED 5 (16.1%) 14 (17.7%) 1.000
Bio+IM 1 (3.2%) 7 (8.9%) 0.437
Bio+ED 4 (12.9%) 9 (11.4%) 1.000
ED+IM 2 (6.5%) 1 (1.3%) 0.191
Bio+IM+ED 2 (6.5%) 2 (2.5%) 0.315
ADisease onset, location, and behavior are reported according to the Montreal classification.
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To determine whether this correlation was universal, we next analyzed the correla-
tion of  LRRK2 M2397T and Paneth cell defects in the North American CD cohort (with 
wild-type NOD2 as described above). Surprisingly, there was no association between 
the numbers of  LRRK2 M2397T risk allele and the degree of  Paneth cell defect (R2 = 
0.02054; P = 0.76; Figure 4D). As ATG16L1 T300A and NOD2 SNPs are known to be 
associated with Paneth cell defects in North American CD cohorts, we performed further 
analyses with the North American CD patients with ATG16L1 T300A and/or NOD2 risk 
alleles (n = 116 with LRRK2 M2397T status available) as well as the patients without any 
risk alleles for ATG16L1 T300A or NOD2 (n = 15 with LRRK2 M2397T status available). 
There was no association of  LRRK2 M2397T and the percentage of  normal Paneth cells when all patients 
(including ATG16L1 T300A and/or NOD2 risk alleles) were analyzed (P = 0.13; Supplemental Figure 3A) 
or when only the subset of  patients without ATG16L1 T300A and NOD2 risk alleles were analyzed (P = 
0.82; Supplemental Figure 3B). However, given the relatively small sample size with wild-type ATG16L1 
T300A and NOD2, further investigation with a greater sample size is needed. Therefore, our data suggest 
that there are dichotomous effects of  the ATG16L1 and LRRK2 susceptibility alleles on Paneth cell defects 
within Japanese and North American CD cohorts. Interestingly, LRRK2 M2397T itself  was not associated 
with outcome (P = 0.5931) (Supplemental Table 2).
Unbiased genome-wide association identified additional candidate genes associated with Paneth cell defect in Japanese 
CD. We subsequently performed an unbiased GWAS  analysis to identify additional potential novel SNPs that 
could be associated with the degree of  Paneth cell defects. Although no SNPs reached genome-wide signifi-
cance (<5 × 10–8), 45 SNPs were identified as candidates (P ≤ 5 × 10–6), as well as 8 nonsynonymous SNPs 
Figure 3. Paneth cell phenotypes correlated with time to disease recurrence after surgery in Japa-
nese Crohn’s disease (CD). The Kaplan-Meier curves of time to disease recurrence after resection was 
determined in the CD cases that received prophylaxis after surgery (n = 76). Patients with type I Paneth 
cell phenotype showed a significantly shorter time to disease recurrence (P = 0.013 by log-rank test).
Figure 4. ATG16L1 T300A and LRRK2 M2397T 
genotypes showed dichotomous effects on Paneth 
cell defects in Japanese and North American Crohn’s 
disease (CD) patients. (A) The numbers of the 
ATG16L1 T300A risk allele did not correlate with the 
percentage of normal Paneth cells (R2 = 0.01717 and P 
= 0.20 by linear regression) in Japanese CD, while (B) 
in North American CD without the common CD-asso-
ciated NOD2 risk allele, the numbers of the ATG16L1 
T300A risk allele correlated with the percentage of 
normal Paneth cells (R2 = 0.04387 and P = 0.0395 by 
linear regression). In contrast, (C) the numbers of the 
LRRK2 M2397T risk allele negatively correlated with 
the percentage of normal Paneth cells in Japanese CD 
(R2 = 0.247, P = 3.62 × 10–4 by linear regression). (D) 
However, in North American CD, the numbers of the 
LRRK2 M2397T risk allele did not correlate with the 
percentage of normal Paneth cells (R2 = 0.02054, P = 
0.76 by linear regression). Error bars represent ± SEM.
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Figure 5. Genome-wide association analysis results for Paneth cell defect in Japanese Crohn’s disease (CD) patients. Locus zoom plots of P values 
around selected top associated SNPs from Paneth cell phenotype regression analysis. The top associated SNPs for (A) ZBTB16, (C) MAFB, and (E) FER 
are shown as purple diamonds and the remaining SNPs are shown as circles, with color indicating the level of linkage disequilibrium (R2) with lead SNP. 
(B, D, and F) Corresponding normal Paneth cells–numbers of risk alleles correlation. Error bars represent ± SEM. (B) P = 2.74 × 10–6; (D) P = 5.11 × 10–7; (F) 
P = 7.22 × 10–7; all by linear regression.
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that had P values less than or equal to 5 × 10–4 (Supple-
mental Figure 4). The candidate SNPs were categorized 
into 9 gene regions (Table 2 includes the 9 top-associated 
SNPs in these regions). Among the 9 candidate genes, 
ZBTB16, MAFB, and FER (Figure 5) were of  particular 
interest. ZBTB16 modulates autophagy by degrading 
Atg14 (35). MAFB is an important transcriptional factor 
for macrophage differentiation (36), and FER plays a role 
in neutrophil chemotaxis (37), both of  which are involved 
in innate immunity and plausibly affect autophagy func-
tions (38, 39). Therefore, genes involved in autophagy 
and innate immunity are candidates for the development 
of  Paneth cell defect in Japanese CD. Further studies in 
additional cohorts are needed to confirm or refute these 
findings. Supplemental Table 4 shows the top functional 
or nonsynonymous SNPs associated with Paneth cell 
defect (P ≤ 5 × 10–4).
Pathway analysis revealed association with autophagy 
and inflammatory cytokines in candidate genes associated 
with Paneth cell defect. To determine the spectrum of  
pathways involved in the genes associated with Pan-
eth cell defect in Japanese CD, we first performed gene 
enrichment, protein interaction, and KEGG pathway 
analyses to explore the biological functions of  the top 
annotated genes corresponding to SNPs associated 
with abnormal Paneth cells with P values less than or 
equal to 1 × 10–3 (n = 288) to obtain an overview of  
these pathways. Our results demonstrate that the gene 
list was enriched for specific molecular functions and 
biological pathways that could be related to Paneth cell 
phenotype. Twelve functional annotation clusters with an enrichment score of  E greater than 1.4 (cor-
responding to unadjusted P value of  0.05) were identified for this gene set (Supplemental Table 5). We 
also used the 288-gene list to generate a protein-protein interaction network (Supplemental Table 6). The 
functional annotation of  the network is shown in Supplemental Figure 5 and the KEGG pathways (P < 
0.05) for these genes are listed in Supplemental Table 7. Many of  the pathways and networks, such as cell 
adhesion and cytoskeletal remodeling, are known to be linked to IBD pathogenesis (4).
We next focused our analysis on the 17 identified candidate genes (LRRK2 and genes described in Table 2 
and Supplemental Table 4). Ingenuity pathway analysis showed that the 17 genes identified can be connected 
in 2 distinct networks (Figure 6). The majority are involved in a gene network regulating PI3K and ERK 
signaling pathways (Figure 6A). Both of  these pathways can regulate the mTOR pathway, a known upstream 
regulator of  autophagy (40, 41). Moreover, in previous studies, mTOR signaling has been linked to stem cell 
health and Paneth cell differentiation (42–44). A second subset of  genes were linked to the TNF-α signaling 
Figure 6. Ingenuity pathway analysis of the genes associ-
ated with Paneth cell defect in Japanese Crohn’s disease (CD) 
patients. The genes include LRRK2 and the candidate genes 
listed in Table 2 and Supplemental Table 4. The intensity of 
the color correlates with the P values. Solid lines indicate 
direct interactions, and dotted lines indicate indirect interac-
tions. Red denotes genes associated with Paneth cell defect 
in Japanese CD (intensity positively correlates with P values). 
Blue denotes inflammatory bowel disease susceptibility genes. 
The majority of the genes associated with Paneth cell defect 
are involved in (A) the PI3K/mTOR pathway, which links to 
autophagy, whereas a minor subset of the genes are involved 
in (B) TNF signaling.
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pathway (Figure 6B), consistent with the central role of  TNF-α in IBD pathogenesis (4, 6, 45). TNF-α has also 
been implicated in the homeostasis of  Paneth cell function (46–49). Therefore, the candidate genes for Paneth 
cell dysfunction in Japanese CD patients potentially act through modulating autophagy and TNF-α signaling. 
We also examined the potential interactions between the 17 identified genes and known CD susceptibility 
genes (6). We found interactions with several IBD susceptibility genes in both networks (6). For example, IBD 
susceptibility genes FYN, HCK, HNF4A, MAPK1, and RPS6KB1 were involved in the PI3K network, which 
included genes MAFB, ADRA1D, PRLR, ACTR3B, CEP192, CAND2, FOXM1, MFSD1, and RP1L1 that were 
identified in this study. Likewise, IBD susceptibility genes IFNG, IL6ST, LRRK2, and CEBPB, as well as genes 
identified in this study LRRK2, ZBTB16, FBLN1, and EYA1, were involved in the TNF-α network. Therefore, 
the genes identified in this study potentially act in concert with known IBD susceptibility genes in autophagy 
and TNF-α signaling networks in association with Paneth cell defect.
Discussion
We have previously shown that Paneth cell phenotypes are associated with CD susceptibility alleles, path-
ological hallmarks, unique transcriptomic and mucosal microbiome changes, and outcome in patients 
undergoing surgery in North American CD (19, 20). However, it was unclear whether similar associations 
would be present in CD patients from different genetic/ethnic backgrounds, particularly as the incidence of  
CD in other ethnic groups has continued to rise (50, 51). In the current study, we first set out to determine 
the prevalence, and the genetic and clinical associations, of  Paneth cell defect in Japanese CD, a population 
who possess a distinct spectrum of  susceptibility genes compared with European ancestry CD. We demon-
strated that not only was Paneth cell defect prevalent in the Japanese CD, clinically it also correlated with 
prognosis in Japanese CD patients after surgery. Surprisingly, there were dichotomous effects of  ATG16L1 
and LRRK2 between the 2 cohorts. We also identified several associated SNPs in genes linked to autophagy 
and TNF-α signaling as candidates for Paneth cell defect in the Japanese CD.
While ATG16L1 T300A was associated with defective Paneth cells in both mouse models and North 
American adult CD patient cohorts (18, 52, 53), this genetic association was not observed in Japanese CD. 
In contrast, we found that LRRK2 M2397T, a susceptibility allele for European ancestry but not for Japa-
nese or Korean CD (3, 23, 25, 33, 54), was associated with Paneth cell defect in Japanese, but not North 
American CD. There are several important considerations when interpreting these findings. First, given the 
different allele frequencies of  ATG16L1 T300A between European and Asian CD cohorts (5), it is possible 
that a larger sample size is required to achieve sufficient power to detect an association between ATG16L1 
T300A with Paneth cell defect in Japanese CD. Second, while LRRK2 M2397T is not a susceptibility allele 
for Japanese CD, it could also represent a power issue in the Japanese populations. In addition, it is possible 
that LRRK2 M2397T, a missense variant that could result in functional defect of  LRRK2, may be associated 
with other aspects of  CD manifestations. A recent study in leprosy (a granulomatous disease) showed that 
patients harboring the same LRRK2 M2397T allele suffer from excessive proinflammatory responses (55). 
Interestingly, overlapping susceptibility loci between CD and mycobacterial infection (particularly leprosy) is 
established (3). A longitudinal study would provide additional insight into the clinical relevance of  LRRK2 
M2397T in Japanese CD. Additional advanced sequencing technologies such as fine mapping and deep 
Table 2. Candidate SNPs and genes associated with Paneth cell defect in Japanese Crohn’s disease by GWAS (P ≤ 5 × 10–6)
dbSNP Chr PositionA (bp) Allele1/2 P value Beta Gene Location
rs12481514 20 4225920 A/G 2.52 × 10–7 4.469 ADRA1D intronic
rs723080 20 39357465 C/T 5.11 × 10–7 −4.754 MAFB upstream
rs147629807 5 107889038 -/T 7.22 × 10–7 −8.139 FER upstream
rs17318450 5 35482314 A/G 1.62 × 10–6 −5.826 PRLR upstream
rs12494894 3 158596415 A/G 2.25 × 10–6 −6.381 MFSD1 downstream
rs629922 11 114064825 C/T 2.74 × 10–6 4.142 ZBTB16 intronic
rs72622838 8 72100325 A/G 3.04 × 10–6 −4.181 EYA1 downstream
rs11978753 7 152717110 G/T 3.65 × 10–6 −5.941 ACTR3B downstream
rs2238823 22 45936320 A/G 3.80 × 10–6 −5.626 FBLN1 intronic
APositions are based on the Genome Reference Consortium human build 37 (GRCh37). Chr, chromosome.
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sequencing of  the LRRK2 gene and expression quantitative trait loci analysis will be important to validate 
the association of  the M2397T SNP with Paneth cell defect, as has been shown in other studies (22, 29).
Using mouse models, we previously showed that Paneth cell defect is the result of  gene and environ-
ment interactions, suggesting that proper environmental triggers or genetic context may be required to illicit 
Paneth cell defect in CD patients. The sharp contrast of  divergent correlations of  ATG16L1 T300A and 
LRRK2 M2397T with Paneth cell defects in North American and Japanese CD cohorts suggests that the 
environmental factors that the North American and Japanese CD patients harboring these variants encoun-
tered could be distinct. Furthermore, based on our current understanding of  the autophagy machinery, in 
complex biologic processes such as Paneth cell function and intestinal homeostasis, the functions of  these 
autophagy-associated genes may need to be orchestrated in distinct fashions depending on the environ-
mental insults unique to these populations (56). One important direction is to use Paneth cell phenotype 
analysis as a platform to identify potential environmental factors or additional genetic factors that interact 
with specific host mutants in triggering Paneth cell defect in CD patients and mouse models with LRRK2 
deficiency. In addition, environmental and genetic factors that could exert a protective effect of  Paneth 
cell defect should be investigated through large-scale studies. Also of  particular interest is to compare the 
Paneth cell phenotype in first- and second-generation Asian immigrants to North America (and vice versa), 
an approach that has yielded insight into disease pathogenesis in epidemiological studies (57–60). Based 
on our finding, we predict that while the genetic landscape of  the second-generation immigrants will be 
similar to their parents, the genetic correlation to Paneth cell defects will trend more toward European 
ancestry North American CD. In addition, conducting genetic–Paneth cell defect analysis with focused 
ethnic groups (e.g., Ashkenazi Jewish) (61, 62) and with cross-ethnic groups (5) may provide additional 
insight into potential gene-gene interactions in triggering Paneth cell defect.
Among the candidate genes shown to be associated with Paneth cell defects by hypothesis-free associa-
tion, ZBTB16, MAFB, and FER have been shown to be linked to autophagy and components of  the innate 
immune response that could be modulated with autophagy. ZBTB has been shown to regulate autophagy by 
mediating the proteasomal degradation of  Atg14L (35). ZBTB16 is also involved in type 2 innate lymphoid 
cell function (63), NKT cell differentiation (64), and regulation of  inflammatory signaling (65). MAFB is 
associated with macrophage differentiation (36, 66). FER plays a role in leukocyte recruitment and intestinal 
barrier function in response to bacterial lipopolysaccharide recognition (67). Both macrophage differentiation 
and leukocyte recruitment are important elements of  innate immunity and involves autophagy (38, 39). Thus, 
the observation that genes involved directly and indirectly in autophagy were candidates for Paneth cell defect 
supports the notion that autophagy is a central pathway that controls the intestinal homeostasis (68).
We and others have found that molecular changes in processes such as autophagy and TNF signaling 
converge to affect Paneth cell function in CD patients and mouse models of  intestinal inflammation (19, 
45, 52, 69, 70). This in turn correlates with the development of  dysbiosis and inflammation (20). Together, 
these studies suggest that, at least in a subset of  CD patients, Paneth cells are the origin of  intestinal inflam-
mation (10). Future studies that examine the transcriptomic and signaling pathways of  Paneth cells from 
patients with different genetic backgrounds will provide additional insight.
Importantly, although the SNPs for Paneth cell defect identified in this study were largely distinct from 
the known SNPs for European ancestry CD, Paneth cell phenotype still correlated with prognosis in Japa-
nese CD patients undergoing surgery. These results indicate that Paneth cell phenotype, as an integrated 
readout for combinatorial effect of  host genetics and environmental factors, could potentially be applied 
as a universal prognostic biomarker for CD patients of  different ethnicity/genetic backgrounds undergoing 
resection. Of  note, a recent study has highlighted that the genes associated with CD susceptibility and prog-
nosis are distinct (71). Therefore, development of  a potential gene score that predicts postoperative recur-
rence may be complementary to using Paneth cell phenotype as biomarker. In addition, while we did not 
observe the correlation between Paneth cell phenotype and the presence of  granuloma, we did observe a 
trend between diminished Paneth cells and granuloma, a finding that was significant in our previous study 
in North American CD (19). Therefore, future studies with a larger sample size may provide more insight.
In summary, we demonstrated that Paneth cell defect was prevalent in Japanese CD, was associated with 
different spectrum of  genes compared with North American CD, and was predictive of  prognosis. The genes 
involved in Paneth cell defect in Japanese CD mainly affect autophagy and TNF signaling pathways. Paneth 
cell phenotype can be applied as a universal clinical and biological relevant biomarker for CD patients with 
diverse genetic backgrounds.
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Methods
Subjects. A total of  110 Japanese patients with CD were included in this study. All patients were diagnosed 
with CD and underwent ileal resection at Tohoku University Hospital (Sendai, Japan) between 2003 and 
2014. The self-reported ethnicity of  all patients was Japanese. The diagnosis of  CD was made based on 
clinical symptoms and endoscopic, radiographic, and histological findings according to conventional cri-
teria proposed by the Japanese Ministry of  Health, Labour and Welfare (72). Demographics and clinical 
parameters (including clinical phenotype by Montreal classification, medication received prior to and after 
surgery, time to disease recurrence after resection) were extracted from the medical records blinded to Pan-
eth cell phenotypes.
In addition, a total of  164 CD patients who underwent ileal resection were recruited at Washington 
University School of  Medicine between 2005 and 2013, including a subset of  patients (n = 50) that were 
previously reported (19).
Paneth cell phenotype analysis. Ileal resection samples previously collected as part of  standard diagnostic 
procedures and stored in Pathology Department archives at Tohoku University and Washington Univer-
sity were used for Paneth cell phenotype determination. The specimens were processed as formalin-fixed, 
paraffin-embedded (FFPE) tissue blocks stored at 24°C as per routine surgical pathology practice. To be 
included in the study, the proximal margin tissue resection samples must have contained at least 50 well-
oriented intestinal crypts (73) as determined by a pathologist (T.C.L.). Paneth cell phenotype was deter-
mined by defensin-5 immunofluorescence, using defensin-5 antibody (clone 8C8; dilution 1:2,000; Novus 
Biologicals, catalog NB110) followed by donkey anti-mouse Alexa 488 antibody (dilution 1: 500; Thermo 
Fisher Scientific, catalog A-21202) as previously described (20). For a subset of  cases, costaining with 
lysozyme immunofluorescence was performed using lysozyme antibody (clone C-19; dilution 1:100; Santa 
Cruz Biotechnology, catalog sc-27958) followed by donkey anti-goat Alexa 594 antibody (dilution 1: 500; 
Thermo Fisher Scientific, catalog A-11058). Each Paneth cell was classified as normal or abnormal based 
on the morphology of  the cytoplasmic granules (19, 20, 73). For prognostic correlation, the overall Paneth 
cell phenotype for each patient was then defined as following: type I Paneth cell phenotype was defined 
as greater than or equal to 20% abnormal Paneth cells, whereas type II Paneth cell phenotype was defined 
as less than 20% abnormal Paneth cells (19, 20, 73). The cutoff  of  20% was based on the analysis of  106 
non-IBD cases, which showed that the mean percentage of  normal Paneth cells was 80.63 (± 1.17 SEM). 
The cutoff  was used in our previous studies involving North American CD cohorts (19, 20, 73). Paneth 
cell phenotype analysis was performed by a pathologist (T.C.L.) who was blinded to the identification and 
clinical phenotype of  the cases.
Definitions of  clinical remission and clinical relapse. Time from index ileal resection surgery of  CD to 
relapse was calculated. Endoscopy and/or computed tomography were performed when the patients had 
symptoms indicating recurrence (i.e., abdominal pain, worsening of  diarrhea, fever, body weight loss, nau-
sea, and appetite loss), or at least once per year if  the patients had no symptoms.
Definitions of  recurrence were made by endoscopy and/or radiology. Endoscopic recurrence was defined 
as postoperative Rutgeerts score of  i2 or more. Radiologic recurrence was defined by computed tomography 
showing bowel wall thickening (defined as a thickness > 5 mm) or enhancement, fistulas, intra-abdominal 
abscess, and bowel obstruction. All computed tomography scans were reviewed by 2 radiologists. Patients 
who received immunomodulators (thiopurines), biologics (infliximab or adalimumab), or elemental diet 
(more than 600 kcal/day) (74) after resection were considered to have received postoperative prophylaxis.
Genotyping. For Japanese CD patients, genomic DNA was obtained from peripheral blood leuko-
cytes by standard phenol–chloroform extraction and precipitation or by utilizing an NA1000 Automated 
Nucleic Acid Extraction Machine (Kurabo) or PAXgene DNA Kit (BD). The genome-wide SNP geno-
types of  the Japanese CD patients were determined by the Japonica array, a SNP array designed specifi-
cally for the Japanese population (75). The array contains 659,253 SNPs, including tag SNPs for impu-
tation, as well as SNPs related to phenotypes from previously reported GWAS and pharmacogenomics 
studies. As a part of  quality control (QC) measures, SNPs with call rate less than 95% and samples 
with genotyping rates less than 95% were excluded from further analysis. Following SNP and sample 
QC, genotype data of  643,496 SNPs from 98 CD cases were available for further analysis. For North 
American CD patients, genomic DNA was extracted from whole blood (n = 50) as described above or 
from FFPE tissue using a QIAamp DNA FFPE Tissue kit (QIAGEN) (n = 114). For cases where whole 
blood was used for genomic DNA extraction, genotyping was performed with Immunochip as previously 
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described (19). For cases where FFPE tissue was used for genomic DNA extraction, genotyping was 
performed with Taqman SNP genotyping assays (Thermo Fisher Scientific).
Imputation. Untyped genotypes were imputed in the GWAS samples using IMPUTE2 (version 2.3.2) 
and 1,070 healthy individuals from Japan (1KJPN panel, which contains > 20 million SNPs) (76) as a refer-
ence dataset. SNPs with low imputation quality (with a posterior probability score of  < 0.90), minor allele 
frequency less than 0.10 and Hardy-Weinberg equilibrium P value less than 1 × 10–5 were excluded. After 
exclusion, genotype data of  4,198,245 SNPs from 98 Japanese CD cases were used for further analysis.
Pathway and network analysis. Gene enrichment and network analysis was performed on the top 288 
annotated genes corresponding to the SNPs with P less than or equal to 1 × 10–3 (from linear regression) 
using online bioinformatics tools DAVID (https://david.ncifcrf.gov/tools.jsp) and STRING (http://www.
string-db.org/). Functional annotation clusters corresponding to the gene list were identified using DAVID. 
Protein-protein interaction (PPI) network for the 288 genes was extracted using STRING. An annota-
tion network was constructed by combining function-based information with PPI network information 
and visualized using Cytoscape (www.cytoscape.org). Corresponding pathways (P < 0.05) were annotated 
using the enrichment analysis tool in STRING. Core pathway analysis of  the 17 candidate genes was per-
formed using Ingenuity Pathway Analysis software (QIAGEN).
Statistics. The percentages of  normal Paneth cells between North American CD and Japanese CD were 
compared by unpaired t test, and the prevalence of  type I Paneth cell phenotype between the 2 groups 
was compared using Fisher’s exact test. For genotype–Paneth cell defect correlation, we first adopted a 
hypothesis-driven approach with selected SNPs (Figure 1). These SNPs include: (a) 45 SNPs shown to 
have CD-specific susceptibility from an ImmunoChip study examining European ancestry CD (3); (b) an 
additional 38 SNPs reported in European and East Asian ancestry CD (5); (c) 14 SNPs associated with 
East Asian (Japanese and/or Korean) CD through GWAS analyses (21, 23, 28, 77) and deep-resequencing 
analysis (22); and (d) 2 functional CD-associated variants that were either reported to be associated with 
Paneth cell defect in our previous studies (18, 19), or whose genes involved had been implicated to be asso-
ciated with Paneth cell biology in preclinical studies (17, 29). By excluding duplicates, a total of  73 SNPs 
were compiled as candidates. Among the 73 SNPs, 14 SNPs were very rare (minor allele frequency < 1.0%) 
or nonpolymorphic (i.e., NOD2 variants) in East Asian, and 3 SNPs were not constructed/included on 
the Japonica array. After excluding these 17 SNPs, a final 56 SNPs were selected for the hypothesis-driven 
approach. After Bonferroni correction, SNPs with P values less than 8.93 × 10–4 were considered signifi-
cant. For hypothesis-driven analyses, we correlated the genotypes with the percentage of  normal Paneth 
cells by linear regression.
For the subsequent unbiased, GWAS analysis (Figure 1), linear regression was performed using PLINK 
v1.07 software (78). SNPs with P values less than 5 × 10–8 were considered genome-wide significant. SNPs 
with P values less than 5 × 10–6 and nonsynonymous SNPs with P values less than 5 × 10–4 were considered 
candidates with nominal significance.
SNPs located within 100 kbp were considered to be in 1 region. Genes within 200 kbp of  candidate 
SNPs were investigated. Correlation with time to disease recurrence after surgery was performed using the 
log-rank test and Cox-proportional hazards model. Manhattan plots were generated using the R package 
qqman, regional association plots were generated using LocusZoom application (79). All statistical analy-
ses, except genome-wide linear regression, were performed using JMP 11 (SAS Institute Inc.), GraphPad 
Prism (version 6.5), or R software (version 3.1.3).
Power calculation. Using the software Quanto, we calculated the power of  the current study to detect 
genetic variants associated with the Paneth cell phenotype, and demonstrated that in the Japanese cohort, 
we have a power of  80.66% to detect a variant with variance contribution of  0.07 at 0.05 significance 
threshold for the hypothesis-driven approach. In the Washington University cohort, we have a power of  
82.65% to detect a variant with variance contribution of  0.05 with a significance threshold of  0.05. At 
genome-wide significance threshold (5 × 10–8), the Japanese cohort has a power of  56.91% to detect a vari-
ant with variance contribution of  0.247.
Study approval. The study was approved by the Ethics Committee of Tohoku University Graduate School 
of Medicine under protocol number 2013-1-539 and the IRB of Washington University School of Medicine 
under protocol number 201209047. Subjects provided informed consent prior to their participation in the study.
Data depository. The accession number for the genotyping data deposition at NCBI Gene Expression 
Omnibus repository is GSE90102.
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